Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Common Equity: 2009-2021

Historic Common Equity for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $78.2 million.

  • Avadel Pharmaceuticals' Common Equity fell 112.57% to -$12.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$12.4 million, marking a year-over-year decrease of 112.57%. This contributed to the annual value of $78.2 million for FY2021, which is 51.78% down from last year.
  • As of FY2021, Avadel Pharmaceuticals' Common Equity stood at $78.2 million, which was down 51.78% from $162.3 million recorded in FY2020.
  • In the past 5 years, Avadel Pharmaceuticals' Common Equity registered a high of $162.3 million during FY2020, and its lowest value of -$29.2 million during FY2019.
  • In the last 3 years, Avadel Pharmaceuticals' Common Equity had a median value of $78.2 million in 2021 and averaged $70.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 1,150.32% in 2019, then spiked by 655.72% in 2020.
  • Avadel Pharmaceuticals' Common Equity (Yearly) stood at $85.6 million in 2017, then crashed by 96.75% to $2.8 million in 2018, then crashed by 1,150.32% to -$29.2 million in 2019, then surged by 655.72% to $162.3 million in 2020, then crashed by 51.78% to $78.2 million in 2021.